Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Explore the impact of AI in drug discovery as 2026 promises critical clinical results and industry transformations.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...

"Dosing the first patient in Phase III represents a major milestone for MDR-001 and for AI-enabled drug development," said Zhangming Niu, Founder and Chief Executive Officer of MindRank. "We believe ...

AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.

A new review titled Artificial Intelligence and the Discovery of Antibiotics: Reinventing with Opportunities, Challenges, and ...

CLEVELAND, OHIO, OH, UNITED STATES, February 24, 2026 /EINPresswire.com/ -- The Bommer Group, a life sciences-focused ...

Integrating AI with advanced robotics to create self-driving labs (SDL) is a promising approach to tackling molecular ...

Explore the latest advancements in Alzheimer’s drug research, revealing hope for earlier diagnosis and new treatment options.

LIGAND-AI is a flagship project of the Target 2035 initiative, funded by the Innovative Health Initiative, a public-private partnership (PPP) between the European Union and the European life science ...

AI is everywhere these days, and though there’s debate about how useful it is, one area where experts think it could be game-changing is scientific research. It promised to be particularly useful for ...